MX2015011576A - Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. - Google Patents
Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos.Info
- Publication number
- MX2015011576A MX2015011576A MX2015011576A MX2015011576A MX2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A MX 2015011576 A MX2015011576 A MX 2015011576A
- Authority
- MX
- Mexico
- Prior art keywords
- thienopyrimidine
- methods
- compositions
- thienopyridine compounds
- mll1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361780099P | 2013-03-13 | 2013-03-13 | |
| PCT/US2014/022750 WO2014164543A1 (en) | 2013-03-13 | 2014-03-10 | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015011576A true MX2015011576A (es) | 2016-05-16 |
Family
ID=51529943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011576A MX2015011576A (es) | 2013-03-13 | 2014-03-10 | Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9505781B2 (https=) |
| EP (1) | EP2968342B1 (https=) |
| JP (2) | JP2016512514A (https=) |
| KR (1) | KR20150130389A (https=) |
| CN (1) | CN105188705A (https=) |
| AU (1) | AU2014249233A1 (https=) |
| BR (1) | BR112015022602A2 (https=) |
| CA (1) | CA2904612A1 (https=) |
| IL (1) | IL241193A0 (https=) |
| MX (1) | MX2015011576A (https=) |
| WO (1) | WO2014164543A1 (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102215272B1 (ko) * | 2012-09-28 | 2021-02-15 | 이그니타, 인코포레이티드 | 비정형 단백질 키나제 c의 아자퀴나졸린 억제제 |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| USRE49687E1 (en) | 2014-09-09 | 2023-10-10 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016081732A1 (en) * | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| TWI703150B (zh) * | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| HK1246593A1 (zh) * | 2015-06-04 | 2018-09-14 | Kura Oncology, Inc. | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| US10869868B2 (en) * | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PL3429591T3 (pl) * | 2016-03-16 | 2023-07-17 | Kura Oncology, Inc. | Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| JP6991585B2 (ja) | 2016-05-02 | 2022-01-12 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | メニン阻害剤としてのピペリジン |
| WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
| EP3512857B1 (en) * | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro bicyclic inhibitors of menin-mll interaction |
| CA3033020A1 (en) * | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-mll interaction |
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| EA039109B1 (ru) * | 2016-12-07 | 2021-12-06 | Кура Онколоджи, Инк. | Мостиковые бициклические ингибиторы взаимодействия менин-mll и способы применения |
| CN110248946B (zh) * | 2016-12-15 | 2023-05-23 | 詹森药业有限公司 | Menin-MLL相互作用的氮杂环庚烷抑制剂 |
| WO2018109088A1 (en) | 2016-12-15 | 2018-06-21 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-mll interaction |
| EA038388B1 (ru) * | 2017-01-16 | 2021-08-19 | Кура Онколоджи, Инк. | Замещенные ингибиторы менина-mll и способы применения |
| WO2018175746A1 (en) * | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
| MX2019011412A (es) | 2017-03-31 | 2020-02-07 | Univ Michigan Regents | Piperidinas como inhibidores de menina covalentes. |
| WO2018226976A1 (en) | 2017-06-08 | 2018-12-13 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with mll proteins |
| EP3684361A4 (en) * | 2017-09-20 | 2021-09-08 | Kura Oncology, Inc. | SUBSTITUTED INHIBITORS OF MENIN-MLL AND METHOD OF USING |
| JP7307729B2 (ja) * | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤 |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| ES2991898T3 (es) * | 2018-08-08 | 2024-12-05 | Sumitomo Pharma Co Ltd | Derivado de piperidina con puente ópticamente activo |
| CA3112340A1 (en) | 2018-10-03 | 2020-04-09 | The Regents Of The University Of Michigan | Small molecule menin inhibitors |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| AU2019395201A1 (en) * | 2018-12-06 | 2021-05-20 | Daiichi Sankyo Company, Limited | Cycloalkane-1,3-diamine derivative |
| WO2020132384A1 (en) | 2018-12-21 | 2020-06-25 | Celgene Corporation | Thienopyridine inhibitors of ripk2 |
| CN113677341B (zh) * | 2019-02-01 | 2024-07-05 | 南卡罗莱纳大学 | 双环吡啶组合物及其用于癌症治疗的方法 |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3142351A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN112116960B (zh) * | 2019-06-20 | 2024-10-11 | 中国石油化工股份有限公司 | 柴油加氢反应的组分含量确定方法、装置 |
| WO2021067215A1 (en) | 2019-09-30 | 2021-04-08 | Agios Pharmaceuticals, Inc. | Piperidine compounds as menin inhibitors |
| UA129778C2 (uk) | 2019-10-28 | 2025-07-30 | Мерк Шарп Енд Доум Елелсі | Низькомолекулярні інгібітори g12c-мутантного kras |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021106231A1 (en) * | 2019-11-29 | 2021-06-03 | Taiho Pharmaceutical Co., Ltd. | A compound having inhibitory activity against kras g12d mutation |
| TW202525813A (zh) | 2019-12-19 | 2025-07-01 | 比利時商健生藥品公司 | 經取代之直鏈螺環接衍生物 |
| CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| TW202204333A (zh) | 2020-04-08 | 2022-02-01 | 美商阿吉歐斯製藥公司 | Menin抑制劑及治療癌症之使用方法 |
| WO2021207310A1 (en) | 2020-04-08 | 2021-10-14 | Agios Pharmaceuticals, Inc. | Menin inhibitors and methods of use for treating cancer |
| TW202200589A (zh) | 2020-05-28 | 2022-01-01 | 瑞士商諾華公司 | Ｍｌｌ１抑制劑及抗癌劑 |
| EP4232020A4 (en) * | 2020-10-21 | 2024-08-07 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
| CA3215379A1 (en) | 2021-05-08 | 2022-11-17 | Olivier Alexis Georges Querolle | Substituted spiro derivatives |
| US20240417405A1 (en) | 2021-05-08 | 2024-12-19 | Janssen Pharmaceutica Nv | Substituted Spiro Derivatives |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| IL308862A (en) | 2021-06-01 | 2024-01-01 | Janssen Pharmaceutica Nv | Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories |
| JP2024521902A (ja) | 2021-06-03 | 2024-06-04 | ヤンセン ファーマシューティカ エヌ．ベー． | スピロ環状アミンで置換されたピリダジン又は１，２，４－トリアジン |
| WO2022262796A1 (en) | 2021-06-17 | 2022-12-22 | Janssen Pharmaceutica Nv | (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-m ethylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer |
| CN115515958B (zh) * | 2021-08-04 | 2023-09-29 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023011446A1 (zh) * | 2021-08-04 | 2023-02-09 | 成都苑东生物制药股份有限公司 | 一种新型磺酰胺类menin-MLL相互作用抑制剂、其制备方法及医药用途 |
| WO2023056589A1 (en) | 2021-10-08 | 2023-04-13 | Servier Pharmaceuticals Llc | Menin inhibitors and methods of use for treating cancer |
| CA3244647A1 (en) * | 2021-12-31 | 2025-06-13 | Hitgen Inc. | MENINO-MLL INHIBITOR AND ITS USE |
| WO2023215354A1 (en) * | 2022-05-03 | 2023-11-09 | Board Of Regents, The University Of Texas System | Menin proteolysis targeting chimeras (protacs) |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN116199633B (zh) * | 2022-12-27 | 2024-05-31 | 甘肃省化工研究院有限责任公司 | 一种制备瑞维鲁胺的方法 |
| AU2024361909A1 (en) | 2023-10-20 | 2026-03-26 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003022214A2 (en) * | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
| US7612078B2 (en) * | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| US20050222175A1 (en) * | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| EP1947103A1 (en) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments |
| CN102186479A (zh) * | 2008-09-10 | 2011-09-14 | 凯利普西斯公司 | 用于治疗疾病的组胺受体的氨基嘧啶抑制剂 |
| EP2459533A4 (en) * | 2009-07-30 | 2013-01-16 | Univ Singapore | SMALL MOLECULAR ISOPRENYLCYSTONE CARBOXYL METHYLTRANSFERASE HEMMER WITH POTENTIAL ANTIBODY EFFECT |
| CN102984941B (zh) | 2009-09-04 | 2016-08-17 | 密执安大学评议会 | 用于治疗白血病的组合物和方法 |
| GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
-
2014
- 2014-03-10 WO PCT/US2014/022750 patent/WO2014164543A1/en not_active Ceased
- 2014-03-10 US US14/773,686 patent/US9505781B2/en active Active
- 2014-03-10 KR KR1020157027855A patent/KR20150130389A/ko not_active Withdrawn
- 2014-03-10 US US14/203,233 patent/US9216993B2/en active Active
- 2014-03-10 EP EP14779908.4A patent/EP2968342B1/en active Active
- 2014-03-10 MX MX2015011576A patent/MX2015011576A/es unknown
- 2014-03-10 BR BR112015022602A patent/BR112015022602A2/pt not_active IP Right Cessation
- 2014-03-10 JP JP2016501053A patent/JP2016512514A/ja not_active Withdrawn
- 2014-03-10 CN CN201480025177.5A patent/CN105188705A/zh active Pending
- 2014-03-10 AU AU2014249233A patent/AU2014249233A1/en not_active Abandoned
- 2014-03-10 CA CA2904612A patent/CA2904612A1/en not_active Abandoned
-
2015
- 2015-09-06 IL IL241193A patent/IL241193A0/en unknown
- 2015-11-10 US US14/937,421 patent/US9505782B2/en active Active
-
2016
- 2016-10-18 US US15/296,842 patent/US10160769B2/en active Active
-
2018
- 2018-05-01 JP JP2018088243A patent/JP6670885B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6670885B2 (ja) | 2020-03-25 |
| US20160137665A1 (en) | 2016-05-19 |
| US20170253611A1 (en) | 2017-09-07 |
| WO2014164543A1 (en) | 2014-10-09 |
| US9505781B2 (en) | 2016-11-29 |
| IL241193A0 (en) | 2015-11-30 |
| CA2904612A1 (en) | 2014-10-09 |
| US9216993B2 (en) | 2015-12-22 |
| AU2014249233A1 (en) | 2015-09-24 |
| US10160769B2 (en) | 2018-12-25 |
| US20140275070A1 (en) | 2014-09-18 |
| BR112015022602A2 (pt) | 2017-07-18 |
| EP2968342B1 (en) | 2018-10-03 |
| EP2968342A4 (en) | 2016-07-27 |
| US20160046647A1 (en) | 2016-02-18 |
| US9505782B2 (en) | 2016-11-29 |
| JP2016512514A (ja) | 2016-04-28 |
| JP2018115214A (ja) | 2018-07-26 |
| CN105188705A (zh) | 2015-12-23 |
| KR20150130389A (ko) | 2015-11-23 |
| EP2968342A1 (en) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015011576A (es) | Composiciones que comprenden compuestos de tienopirimidina y tienopiridina y metodos para usar los mismos. | |
| ZA202310395B (en) | Substituted inhibitors of menin-mll and methods of use | |
| MY186712A (en) | Methods and compositions for inhibiting the interaction of menin with mll proteinss | |
| HK1246593A1 (zh) | 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物 | |
| PH12018501955A1 (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
| MY193249A (en) | Anti-human cd19 antibodies with high affinity | |
| IN2015DN00127A (https=) | ||
| MX356107B (es) | Histidil-arnt sintetasas para tratar enfermedades autoinmunes e inflamatorias. | |
| JOP20140141B1 (ar) | استخدام 3،2- ثنائي هيدروإيميدازول-[2،1-c] كونازولينات مستبدلة لمعالجة الاورام الليمفاوية | |
| MX2015006324A (es) | Metodos para la fabricacion de polipeptidos proteoliticamente procesados. | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
| UA117470C2 (uk) | Заміщені ксантини та способи їх застосування | |
| PH12016500643B1 (en) | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c'] DIPYRROL-2-YL | |
| PH12014501605A1 (en) | Anti-lrp5 antibodies and methods of use | |
| MX2016004945A (es) | Procesos para la preparacion de compuestos plaguicidas. | |
| MX392001B (es) | Composiciones fertilizantes y métodos para hacer y utilizar las mismas. | |
| MX2016005285A (es) | Conjugados de somatostatina y sus analagos. | |
| MX2015009818A (es) | Agonistas de receptores gamma activados por el proliferador de peroxisoma para el tratamiento de esclerosis multiple. | |
| MX357675B (es) | Anticuerpos anti-jagged y métodos de uso. | |
| EP3888671A3 (en) | Protein formulations | |
| MX2015016603A (es) | Composiciones de corticosteroides. | |
| EA201892083A1 (ru) | Замещенные ингибиторы менина-mll и способы применения | |
| IES20140280A2 (en) | Human targets II | |
| UA70698U (ru) | Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства |